Vanda Pharmaceuticals, Inc.

420 articles about Vanda Pharmaceuticals, Inc.

• Vanda Pharmaceuticals, Inc. Reports Third Quarter 2009 Results

  11/2/2009

• Vanda Pharmaceuticals, Inc. to Announce Third Quarter 2009 Financial Results on November 2, 2009 Conference Call and Webcast to Follow

  10/29/2009

• Novartis Pharma AG (JOBS) Acquires Exclusive Rights From Vanda Pharmaceuticals, Inc. for Commercialization of Fanapt in the United States and Canada; Novartis to Pay $200 Million Upfront

  10/13/2009

• Vanda Pharmaceuticals, Inc. Posts Wider-Than-Expected Q2 Loss

  8/10/2009

• Vanda Pharmaceuticals, Inc. to Announce Second Quarter 2009 Financial Results on August 10, 2009 Conference Call and Webcast to Follow

  8/7/2009

• Vanda Pharmaceuticals, Inc. to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting

  5/15/2009

• Vanda Pharmaceuticals, Inc. Surges on Fanapt FDA Approval; Stock Up +625.93% at Market Close

  5/7/2009

• Vanda Pharmaceuticals, Inc. Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital

  5/7/2009

• Vanda Pharmaceuticals, Inc. Trims Loss to $6.5 Million

  4/29/2009

• Vanda Pharmaceuticals, Inc. Reports First Quarter 2009 Results

  4/29/2009

• Vanda Pharmaceuticals, Inc. to Fight Shareholder Liquidation Proposal

  2/24/2009

• Vanda Pharmaceuticals, Inc. Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP

  2/24/2009

• Vanda Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Results

  2/11/2009

• Vanda Pharmaceuticals, Inc. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet

  12/2/2008

• FDA Accepts Vanda Pharmaceuticals, Inc. Iloperidone Resubmission and Sets New Action Date

  11/20/2008

• Vanda Pharmaceuticals, Inc. Q3 Loss Narrows; Job Cuts and Suspends Development Activities

  10/30/2008

• Vanda Pharmaceuticals, Inc. Declares Dividend Distribution of Preferred Stock Purchase Rights

  9/25/2008

• Vanda Pharmaceuticals, Inc. Provides Update on Iloperidone; Shares Rise on Plans for FDA Response

  9/11/2008

• Vanda Pharmaceuticals, Inc. Reports Second Quarter 2008 Results

  8/6/2008

• Vanda Pharmaceuticals, Inc. to Announce Second Quarter 2008 Financial Results

  8/1/2008